Five-Drug Anti-HIV Treatment Followed by Treatment Interruption in Patients Who Have Recently Been Infected With HIV

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Keywords

ClinConnect Summary

Acute, primary HIV infection represents a potentially unique opportunity to eradicate the infection. Although plasma viral load rises rapidly, the dominant infecting virus is relatively uniform genetically, and infection may not be fully established in all tissue sites until some time after exposure. Current antiretroviral therapy is able to reduce plasma viral load to unmeasurable levels in established infection. However, there are many questions that remain about the treatment of primary HIV infection. While it is assumed that aggressive antiretroviral regimens are required, it is not kno...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Acute HIV infection (recently infected with HIV or recent seroconversion)
• • Karnofsky status of 80 or greater within 14 days prior to study entry
• • Acceptable methods of contraception
• • Able and willing to give written informed consent
• Exclusion Criteria:
• • Previously received anti-HIV drugs
• • Hepatitis within 30 days prior to study entry
• • Pancreatitis within 120 days prior to study entry
• • Radiation or chemotherapy within 30 days prior to study entry
• • Certain medications within 14 days prior to study entry
• • Experimental or investigational therapy within 30 days prior to study entry
• • Illness (non-HIV infection, cancer, etc.) at the time of study entry
• • Pregnant or breastfeeding